Dr. Reddy's Laboratories Ltd. (RDY)

35.06
0.12 0.34
NYSE : Health Technology
Prev Close 35.18
Open 35.21
Day Low/High 35.01 / 35.85
52 Wk Low/High 31.58 / 42.82
Volume 147.69K
Avg Volume 179.80K
Exchange NYSE
Shares Outstanding 166.06M
Market Cap 5.89B
EPS 1.60
P/E Ratio 21.45
Div & Yield 0.26 (0.75%)
Dr. Reddy’s Announces The Launch Of Lamotrigine Extended-Release Tablets

Dr. Reddy’s Announces The Launch Of Lamotrigine Extended-Release Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Lamotrigine Extended-Release Tablets (25 mg, 50 mg, 100 mg, 200 mg, 300 mg) a therapeutic equivalent generic version of Lamictal ® XR...

DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower

DVAX, RDY, ONXX, ALXN And VRX, 5 Health Care Stocks Pushing The Sector Lower

TheStreet Ratings group highlights 5 stocks pushing the health care sector lower today.

8 Stocks Surging on Big Volume

8 Stocks Surging on Big Volume

Often when above-average volume moves into an equity, it precedes a large spike in volatility.

4 Stocks Raising The Health Care Sector Higher

4 Stocks Raising The Health Care Sector Higher

TheStreet Ratings group highlights 4 stocks pushing the health care sector higher today.

Dr. Reddy’s And Nordion Inc. (formerly MDS Inc.) Settle Claims

Dr. Reddy’s And Nordion Inc. (formerly MDS Inc.) Settle Claims

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it had settled its claims against Nordion Inc.

Dr. Reddy’s Announces The Launch Of Zoledronic Acid Injection

Dr. Reddy’s Announces The Launch Of Zoledronic Acid Injection

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Zoledronic Acid Injection (4 mg/5 mL), a bioequivalent generic version of Zometa ® (zoledronic acid) 4 mg/5 mL Injection in the US...

Dr. Reddy’s Holds 98.6% Of The Shares In OctoPlus After The Post Closing Acceptance Period

Dr. Reddy’s Holds 98.6% Of The Shares In OctoPlus After The Post Closing Acceptance Period

This is a joint press release by Reddy Netherlands B.V.

Dr. Reddy's Q3 & 9 Months FY13 Financial Results

Dr. Reddy's Q3 & 9 Months FY13 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy's Declares Offer For OctoPlus Unconditional

Dr. Reddy's Declares Offer For OctoPlus Unconditional

With reference to the joint press releases of Dr. Reddy’s (NYSE: RDY) and OctoPlus (NYSE Euronext Amsterdam: OCTO), issued on 22 October 2012 and 13 December 2012 respectively, the Offeror and OctoPlus hereby ...

Dr. Reddy's To Release Q3 FY13 Results On February 14, 2013

Dr. Reddy's To Release Q3 FY13 Results On February 14, 2013

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Third Quarter and Nine months ended December 31, 2012 on Thursday, February 14, 2013 after the Board Meeting.

Dr. Reddy’s Announces The Launch Of Desloratadine ODT (Orally Disintegrating Tablets)

Dr. Reddy’s Announces The Launch Of Desloratadine ODT (Orally Disintegrating Tablets)

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Desloratadine ODT (2.

Dr. Reddy’s Announces The Launch Of Finasteride Tablets

Dr. Reddy’s Announces The Launch Of Finasteride Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Finasteride Tablets (1 mg), a bioequivalent generic version of Propecia® (Finasteride) Tablets in the US market on January 02, 2013.

3 Stocks Pushing The Drugs Industry Higher

3 Stocks Pushing The Drugs Industry Higher

TheStreet Ratings group would like to highlight 3 stocks pushing the drugs industry higher today, Nov. 27, 2012.

Dr. Reddy’s Announces The Launch Of SILDENAFIL TABLETS

Dr. Reddy’s Announces The Launch Of SILDENAFIL TABLETS

Dr. Reddy’s Laboratories (NYSE:RDY) announced today that it has launched Sildenafil Tablets (20 mg), a bioequivalent generic version of REVATIO ® (Sildenafil) Tablets in the US market on November 16, 2012, ...

Dr. Reddy’s Q2 & H1 FY13 Financial Results

Dr. Reddy’s Q2 & H1 FY13 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Laboratories Limited Intends To Make A Recommended Public Offer For OctoPlus N.V.

Dr. Reddy’s Laboratories Limited Intends To Make A Recommended Public Offer For OctoPlus N.V.

Dr. Reddy’s Laboratories Limited (NYSE:RDY) (“Dr.

Dr. Reddy's To Release Q2 And Half Year FY13 Results On October 30, 2012

Dr. Reddy's To Release Q2 And Half Year FY13 Results On October 30, 2012

Dr. Reddy's Laboratories (NYSE: RDY) will announce results for the Second Quarter and Half Year ended September 30, 2012 on Tuesday, October 30, 2012 after the Board Meeting.

Dr. Reddy's Custom Pharmaceutical Services (CPS) Business Expands Its Manufacturing Operations In Mirfield, UK

Dr. Reddy's Custom Pharmaceutical Services (CPS) Business Expands Its Manufacturing Operations In Mirfield, UK

The Custom Pharmaceutical Services (CPS) business of Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Announces The Launch Of Montelukast Sodium Oral Granules

Dr. Reddy’s Announces The Launch Of Montelukast Sodium Oral Granules

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Montelukast Sodium Oral Granules, a bioequivalent generic version of Singulair® (montelukast sodium) oral granules in the US market...

Dr. Reddy’s Announces The Launch Of Amoxicillin Tablets, Capsules, And Oral Suspension

Dr. Reddy’s Announces The Launch Of Amoxicillin Tablets, Capsules, And Oral Suspension

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Amoxicillin Tablets, Capsules, and Oral Suspension, a bioequivalent generic version of Amoxil® (Amoxicillin) Tablets, Capsules, and...

Dr. Reddy’s Announces The Launch Of Metoprolol Succinate ER (Extended-Release) Tablets

Dr. Reddy’s Announces The Launch Of Metoprolol Succinate ER (Extended-Release) Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that is has launched Metoprolol Succinate ER (Extended-Release) Tablets (25 mg, 50 mg, 100 mg & 200 mg), a bioequivalent generic version of Toprol-XL ® ...

Dr. Reddy’s Announces The Launch Of Montelukast Sodium Tablets And Montelukast Sodium Chewable Tablets

Dr. Reddy’s Announces The Launch Of Montelukast Sodium Tablets And Montelukast Sodium Chewable Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched Montelukast Sodium Tablets (10 mg) and Montelukast Sodium Chewable Tablets (4 mg & 5 mg), bioequivalent generic versions of ...

Dr. Reddy's Laboratories Management Discusses Q1 2013 Results - Earnings Call Transcript

Dr. Reddy's Laboratories Management Discusses Q1 2013 Results - Earnings Call Transcript

Dr. Reddy's Laboratories Management Discusses Q1 2013 Results - Earnings Call Transcript

Dr. Reddy’s Q1 FY13 Financial Results

Dr. Reddy’s Q1 FY13 Financial Results

Dr. Reddy’s Laboratories Ltd.

Dr. Reddy’s Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy’s Laboratories Limited Announces Filing Of Annual Report On Form 20-F

Dr. Reddy’s Laboratories Limited (NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated financial statements for the fiscal year ended 31 March, 2012 was filed with the ...

Dr. Reddy’s Announces The Launch Of Atorvastatin Calcium Tablets

Dr. Reddy’s Announces The Launch Of Atorvastatin Calcium Tablets

Dr. Reddy’s Laboratories (NYSE: RDY) announced today that it has launched ATORVASTATIN CALCIUM TABLETS 10 mg, 20 mg, 40 mg and 80 mg, a bioequivalent generic version of LIPITOR ® (atorvastatin calcium)...

TheStreet Quant Rating: B- (Buy)